T1	Qualifier 8 30	clinically significant
T2	Condition 31 40	condition
T3	Observation 44 53	situation
T4	Qualifier 59 82	anatomical malformation
T5	Negation 112 122	other than
T6	Condition 123 150	the condition being studied
R1	Has_negation Arg1:T6 Arg2:T5	
T7	Observation 199 235	interfere with the trial evaluations
T8	Observation 199 213;239 260	interfere with optimal participation
*	OR T2 T3
T9	Scope 31 111	condition or situation (eg, anatomical malformation that complicates intubation)
R2	Subsumes Arg1:T3 Arg2:T4	
R3	Has_qualifier Arg1:T9 Arg2:T1	
R4	AND Arg1:T9 Arg2:T6	
*	OR T8 T7
T10	Scope 199 260	interfere with the trial evaluations or optimal participation
R5	Has_scope Arg1:T9 Arg2:T10	
T11	Condition 282 304	neuromuscular disorder
T12	Observation 314 324	affect NMB
T13	Observation 314 320;332 349	affect trial assessments
*	OR T13 T12
T14	Scope 314 349	affect NMB and/or trial assessments
R6	Has_scope Arg1:T11 Arg2:T14	
T15	Condition 355 373	dialysis-dependent
T16	Condition 409 435	severe renal insufficiency
T17	Measurement 448 491	estimated glomerular filtration rate (eGFR)
T18	Value 492 502	<30 ml/min
R7	Has_value Arg1:T17 Arg2:T18	
R8	Subsumes Arg1:T16 Arg2:T17	
T19	Scope 409 503	severe renal insufficiency (defined as estimated glomerular filtration rate (eGFR) <30 ml/min)
*	OR T15 T16
T20	Observation 548 564	personal history
T21	Observation 538 544	family
T22	Condition 568 590	malignant hyperthermia
*	OR T21 T20
T23	Scope 538 564	family or personal history
R9	Has_scope Arg1:T22 Arg2:T23	
T24	Condition 626 633	allergy
T25	Procedure 637 653	study treatments
T27	Drug 682 689	opioids
T28	Drug 690 697	opiates
T29	Drug 699 715	muscle relaxants
T30	Drug 725 735	excipients
*	OR T29 T30 T27 T28 T31 T25 T26
T31	Drug 746 756	medication
T32	Qualifier 740 745	other
R10	Has_qualifier Arg1:T31 Arg2:T32	
T33	Procedure 772 790	general anesthesia
T34	Temporal 765 790	during general anesthesia
R11	Has_temporal Arg1:T31 Arg2:T34	
T26	Drug 667 677	excipients
T35	Scope 637 790	study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia
R12	Has_scope Arg1:T24 Arg2:T35	
T36	Drug 831 841	toremifene
T37	Mood 812 822	planned to
A1	Optional T37
T38	Drug 849 861	fusidic acid
T39	Qualifier 866 883	IV administration
T40	Temporal 884 906;932 965	within 24 hours before administration of study treatment
T41	Temporal 910 965	within 24 hours after administration of study treatment
T42	Reference_point 932 965	administration of study treatment
T43	Reference_point 932 965	administration of study treatment
R13	Has_index Arg1:T40 Arg2:T43	
R14	Has_index Arg1:T41 Arg2:T42	
*	OR T40 T41
T44	Scope 884 965	within 24 hours before or within 24 hours after administration of study treatment
*	OR T38 T36
T45	Scope 831 861	toremifene and/or fusidic acid
R15	Has_qualifier Arg1:T45 Arg2:T39	
R16	Has_scope Arg1:T45 Arg2:T44	
R17	Has_mood Arg1:T45 Arg2:T37	
T46	Drug 1001 1011	sugammadex
T47	Temporal 977 987	previously
T48	Observation 1019 1034;1048 1062	participated in clinical trial
T49	Drug 1037 1047	sugammadex
R18	AND Arg1:T48 Arg2:T49	
*	OR T46 T48
T50	Scope 1001 1062	sugammadex or has participated in a sugammadex clinical trial
R19	Has_temporal Arg1:T50 Arg2:T47	
T51	Observation 1098 1150	has participated in an interventional clinical trial
T52	Observation 1068 1091;1115 1150	currently participating in an interventional clinical trial
*	OR T51 T52
T53	Drug 1159 1183	investigational compound
T54	Device 1187 1193	device
T55	Temporal 1194 1240	within 30 days of signing the informed consent
T56	Reference_point 1212 1240	signing the informed consent
R20	Has_index Arg1:T55 Arg2:T56	
T57	Temporal 1194 1232;1241 1247	within 30 days of signing the informed assent
T58	Reference_point 1212 1232;1241 1247	signing the informed assent
R21	Has_index Arg1:T57 Arg2:T58	
*	OR T57 T55
*	OR T53 T54
T59	Scope 1159 1193	investigational compound or device
T60	Scope 1068 1150	currently participating in or has participated in an interventional clinical trial
R22	Has_scope Arg1:T60 Arg2:T59	
T61	Scope 1194 1247	within 30 days of signing the informed consent/assent
R23	Has_scope Arg1:T60 Arg2:T61	
